Abstract:Background: Melanoma is the most lethal type of skin cancer. Since chemoresistance is a significant barrier, identification of regulators affecting chemosensitivity is necessary in order to create new forms of intervention. Prohibitin 1 (PHB1) can act as anti-apoptotic or tumor suppressor molecule, depending on its subcellular localization. Our recent data shown that accumulation of PHB1 protects melanoma cells from chemotherapy-induced cell death. Lacking of post-transcriptional regulation of PHB1 could explain this accumulation. Interestingly, most of melanoma patients have down-regulation of microRNA-195. Here, we investigate the role of miR-195, its impact on PHB1 expression, and on chemosensitivity in melanoma cells. Methods: TCGA-RNAseq data obtained from 341 melanoma patient samples as well as a panel of melanoma cell lines were used in an expression correlation analysis between PHB1 and predicted miRNAs. miR-195 impact on PHB1 mRNA and protein levels and relevance of this regulation were investigated in UACC-62 and SK-MEL-5 melanoma lines by RT-qPCR and western blot, luciferase reporter and genetic rescue experiments. Cell proliferation, cell-cycle analysis and caspase 3/7 assay were performed to investigate the potential action of miR-195 as chemosensitizer in melanoma cells treated with cisplatin and temozolomide. Results: Analysis of the TCGA-RNAseq revealed a significant negative correlation (Pearson) between miR-195 and PHB1 expression. Moreover, RT-qPCR data showed that miR-195 is down-regulated while PHB1 is up-regulated in a collection of melanoma cells. We demonstrated that miR-195 regulates PHB1 directly by RT-qPCR and western blot in melanoma cells and luciferase assays. To establish PHB1 as a relevant target of miR-195, we conducted rescue experiments in which we showed that PHB1 transgenic expression could antagonize the suppressive effect miR-195 on the proliferation of melanoma cells. Finally, transfection experiments combined with drug treatments performed in the UACC-62 and SK-MEL-5 melanoma cells corroborated miR-195 as potential anti-proliferative agent, with potential impact in sensitization of melanoma cell death. Conclusions: This study support the role of miR-195 as anti-proliferative miRNA via targeting of PHB1 in melanoma cells.

MiR-195 Enhances the Sensitivity of Oral Cancer Cells to Cisplatin (DDP) by Down-Regulating the Expression of MAPK Kinase 1 (MEK1)

MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.

Downregulation of Microrna-17-5p Inhibits Drug Resistance of Gastric Cancer Cells Partially Through Targeting P21.

MiR-222 Targeted PUMA to Improve Sensitization of UM1 Cells to Cisplatin

1069 MicroRNA-143 is a Potential Tumor Suppressor Targeting DNA Methyltransferases 3a in Colorectal Cancer

Downregulation of Microrna 99a in Oral Squamous Cell Carcinomas Contributes to the Growth and Survival of Oral Cancer Cells.

Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway

MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway.

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway

MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1

Differential Expression of MicroRNA MiR-145 and MiR-155 Downstream Targets in Oral Cancers Exhibiting Limited Chemotherapy Resistance

MicroRNA-181a Enhances the Chemoresistance of Human Cervical Squamous Cell Carcinoma to Cisplatin by Targeting PRKCD.

MiR-199a-3p Enhances Cisplatin Sensitivity of Cholangiocarcinoma Cells by Inhibiting Mtor Signaling Pathway and Expression of MDR1

microRNA‐10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer

MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition

Abstract A13: The microRNA-200 family overcomes cisplatin resistance by targeting ceramide glycosylation

miR-185-5p rewires cisplatin resistance by restoring miR- 203a-3p expression via downregulation of SOX9

Expression of miR-195 is associated with chemotherapy sensitivity of cisplatin and clinical prognosis in gastric cancer

MicroRNA-195 Inhibits Proliferation and Metastasis in Renal Cell Carcinoma Via Regulating HMGA1.

Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1